$CYRX
Cryoport, Inc.

2015 Q4 Form 10-Q Financial Statement

#000114420415065948 Filed on November 16, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2014 Q3
Revenue $1.459M $825.0K
YoY Change 49.64% 42.24%
Cost Of Revenue $1.070M $600.0K
YoY Change 44.47% 18.18%
Gross Profit $384.0K $225.0K
YoY Change 63.4% 212.5%
Gross Profit Margin 26.32% 27.27%
Selling, General & Admin $2.835M $1.511M
YoY Change 89.95% 21.79%
% of Gross Profit 738.38% 671.43%
Research & Development $227.8K $89.28K
YoY Change 129.94% -24.62%
% of Gross Profit 59.31% 39.68%
Depreciation & Amortization $80.00K $50.00K
YoY Change 60.0% -19.13%
% of Gross Profit 20.83% 22.22%
Operating Expenses $3.063M $1.600M
YoY Change 92.43% 17.75%
Operating Profit -$2.679M -$1.375M
YoY Change 97.42% 6.84%
Interest Expense $79.95K $7.854K
YoY Change 64.48% -98.47%
% of Operating Profit
Other Income/Expense, Net -$1.347K -$1.876K
YoY Change -29.33%
Pretax Income -$2.760M -$1.385M
YoY Change 96.07% -90.74%
Income Tax $305.00 $0.00
% Of Pretax Income
Net Earnings -$2.760M -$1.385M
YoY Change 96.05% -90.74%
Net Earnings / Revenue -189.2% -167.88%
Basic Earnings Per Share
Diluted Earnings Per Share -$381.7K -$276.0K
COMMON SHARES
Basic Shares Outstanding 7.225M shares 60.04M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.200M $100.0K
YoY Change 550.0% -80.0%
Cash & Equivalents $5.247M $103.3K
Short-Term Investments
Other Short-Term Assets $289.0K $85.31K
YoY Change 188.97% 109.69%
Inventory $52.88K $58.80K
Prepaid Expenses
Receivables $616.8K $408.1K
Other Receivables $0.00 $0.00
Total Short-Term Assets $6.206M $655.5K
YoY Change 343.29% -34.72%
LONG-TERM ASSETS
Property, Plant & Equipment $875.7K $393.4K
YoY Change 191.89% -23.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $0.00
YoY Change
Total Long-Term Assets $1.253M $549.8K
YoY Change 150.51% -27.01%
TOTAL ASSETS
Total Short-Term Assets $6.206M $655.5K
Total Long-Term Assets $1.253M $549.8K
Total Assets $7.459M $1.205M
YoY Change 292.56% -31.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $700.0K
YoY Change 57.14% 16.67%
Accrued Expenses $400.0K $500.0K
YoY Change -33.33% 66.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $1.000M $1.300M
YoY Change -23.08% 1200.0%
Total Short-Term Liabilities $2.468M $2.579M
YoY Change -17.72% 147.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.468M $2.579M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.468M $2.600M
YoY Change -17.72% 11.34%
SHAREHOLDERS EQUITY
Retained Earnings -$92.03M
YoY Change 11.42%
Common Stock $114.3M $90.65M
YoY Change 10.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.990M -$1.374M
YoY Change
Total Liabilities & Shareholders Equity $7.459M $1.205M
YoY Change 292.56% -31.41%

Cashflow Statement

Concept 2015 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$2.760M -$1.385M
YoY Change 96.05% -90.74%
Depreciation, Depletion And Amortization $80.00K $50.00K
YoY Change 60.0% -19.13%
Cash From Operating Activities -$1.400M -$850.0K
YoY Change 30.84% -26.09%
INVESTING ACTIVITIES
Capital Expenditures -$370.0K -$70.00K
YoY Change 600.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$370.0K -$70.00K
YoY Change 600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -40.00K 860.0K
YoY Change -102.31% -40.69%
NET CHANGE
Cash From Operating Activities -1.400M -850.0K
Cash From Investing Activities -370.0K -70.00K
Cash From Financing Activities -40.00K 860.0K
Net Change In Cash -1.810M -60.00K
YoY Change -374.24% -120.69%
FREE CASH FLOW
Cash From Operating Activities -$1.400M -$850.0K
Capital Expenditures -$370.0K -$70.00K
Free Cash Flow -$1.030M -$780.0K
YoY Change -3.74% -31.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
1100000 USD
CY2015Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
1300000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-102696 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
143868 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-341069 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
95371 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-20174 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
25964 USD
us-gaap Cost Of Revenue
CostOfRevenue
1943866 USD
us-gaap Gross Profit
GrossProfit
564313 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4184128 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2938558 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
178020 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
168523 USD
us-gaap Operating Expenses
OperatingExpenses
4362148 USD
us-gaap Operating Expenses
OperatingExpenses
3107081 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3437923 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2542768 USD
us-gaap Interest Expense
InterestExpense
904802 USD
us-gaap Interest Expense
InterestExpense
1136732 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3682 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4346407 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3680423 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3320 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 USD
us-gaap Net Income Loss
NetIncomeLoss
-4349727 USD
us-gaap Net Income Loss
NetIncomeLoss
-3682023 USD
us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
4474348 USD
us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
2468813 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
447878 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6250433 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.61
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5774389 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5001607 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
94026 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
105186 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
351568 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1110013 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1118012 USD
us-gaap Share Based Compensation
ShareBasedCompensation
354452 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-32817 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-1864 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
34043 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
465 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
147252 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-107280 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
41624 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
29101 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 2.&#160;Nature of the Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material. &#160;Cryoport actively&#160;supports points-of-care, contract research organizations, central laboratories, pharmaceutical companies, contract manufacturers and university researchers.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company is a Nevada corporation and its <font style="BACKGROUND: transparent"> common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol &#8220;CYRX.&#8221;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"> Liquidity</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The unaudited condensed consolidated financial statements have been prepared using the accrual method of accounting in accordance with U.S. GAAP. During the six months ended September 30, 2015, we used cash in operations of $2.9 million and had a net loss of $4.3 million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We believe that our cash resources at September 30, 2015, together with the revenues generated from our solutions will be sufficient to sustain our planned operations for the next 12 months. Future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express<sup style="font-style:normal">&#174;</sup> Solutions as well as our ability to establish additional collaborative arrangements. Revenues increased $1.1 million or 62.8% to $2.9 million for the six months ended September 30, 2015, as compared to $1.8 million for the six months ended September 30, 2014. However, we cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing will be completed on a timely basis and on acceptable terms or at all.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2942356 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1774582 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
91336 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7921 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67851 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-335402 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-67851 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8932281 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1576195 USD
CY2011Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
335402 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
5654523 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-266238 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
369581 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103343 USD
cyrx Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued
ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued
4474348 USD
cyrx Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued
ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued
2468813 USD
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 USD
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
1766997 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3896678 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1662564 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
10881 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
11631 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
50000 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
172000 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
48000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
741377 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
9658 USD
CY2015Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
38700 USD
CY2015Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
12200 USD
CY2015Q1 cyrx Discount Price Per Share Percentage
DiscountPricePerSharePercentage
0.2 pure
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
521100 USD
CY2015Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
280400 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
130200 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
28900 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
16100 USD
CY2015Q3 cyrx Accrued Interest Payable
AccruedInterestPayable
0 USD
CY2015Q1 cyrx Accrued Interest Payable
AccruedInterestPayable
4600 USD
cyrx Estimated Base Rent Under Lease
EstimatedBaseRentUnderLease
9500 USD
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20833333 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12270400 shares
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6400000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
cyrx Increase In Revenues
IncreaseInRevenues
1100000 USD
cyrx Percentage Of Revenue Increased
PercentageOfRevenueIncreased
0.628 pure
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company&#8217;s significant estimates include allowances for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20833333 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7170364 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4186999 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1602041 shares
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5025577 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5025577 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7170364 shares
cyrx Discount Price Per Share Percentage
DiscountPricePerSharePercentage
0.2 pure
CY2015Q3 cyrx Consulting Service Fee
ConsultingServiceFee
66200 USD
CY2014Q3 cyrx Consulting Service Fee
ConsultingServiceFee
86000 USD
cyrx Consulting Service Fee
ConsultingServiceFee
140500 USD
cyrx Consulting Service Fee
ConsultingServiceFee
161900 USD
CY2015Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
266100 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Cryoport, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001124524
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
CYRX
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7225364 shares
cyrx Debt Instrument Convertible Beneficial Conversion Feature Related Party Notes Payable
DebtInstrumentConvertibleBeneficialConversionFeatureRelatedPartyNotesPayable
-521056 USD
cyrx Debt Instrument Convertible Beneficial Conversion Feature Related Party Notes Payable
DebtInstrumentConvertibleBeneficialConversionFeatureRelatedPartyNotesPayable
0 USD
cyrx Proceeds From Issuance Common Stock And Warrants Public Offering
ProceedsFromIssuanceCommonStockAndWarrantsPublicOffering
-5938099 USD
cyrx Proceeds From Issuance Common Stock And Warrants Public Offering
ProceedsFromIssuanceCommonStockAndWarrantsPublicOffering
0 USD
cyrx Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation
ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation
54813 USD
cyrx Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation
ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation
0 USD
cyrx Noncash Or Part Noncash Acquisition Fixed Assets Acquired Accounts Payable And Other Accrued Expenses
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredAccountsPayableAndOtherAccruedExpenses
200000 USD
cyrx Noncash Or Part Noncash Acquisition Fixed Assets Acquired Accounts Payable And Other Accrued Expenses
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredAccountsPayableAndOtherAccruedExpenses
0 USD
cyrx Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets
NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets
32074 USD
cyrx Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets
NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets
0 USD
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-03-31
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20833333 shares

Files In Submission

Name View Source Status
0001144204-15-065948-index-headers.html Edgar Link pending
0001144204-15-065948-index.html Edgar Link pending
0001144204-15-065948.txt Edgar Link pending
0001144204-15-065948-xbrl.zip Edgar Link pending
cyrx-20150930.xml Edgar Link completed
cyrx-20150930.xsd Edgar Link pending
cyrx-20150930_cal.xml Edgar Link unprocessable
cyrx-20150930_def.xml Edgar Link unprocessable
cyrx-20150930_lab.xml Edgar Link unprocessable
cyrx-20150930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tlogo.jpg Edgar Link pending
v424458_10q.htm Edgar Link pending
v424458_ex31-1.htm Edgar Link pending
v424458_ex31-2.htm Edgar Link pending
v424458_ex32-1.htm Edgar Link pending